Pakistan Pharma Career Door Newsletter by Dr.Javeriya Ansari

1. Drug information references
play an important role in phar-
macy practice. Check out these
5 online resources to add to
your drug information toolbox!
1-DailyMed
DailyMed is a one-stop-shop
that contains more than 92,000
drug listings including US Food
and Drug Administration (FDA)
approved package inserts. Addi-
tionally, you can report adverse
events to the FDA’s MedWatch
program. If you need to identify
a medication, then you can do
so through the ID tool known as
Pillbox.
2-MedlinePlus
MedlinePlus is a great consumer
health information resource
published by the National Li-
brary of Medicine and available
both in English and Spanish
languages. MedlinePlus con-
tains information on prescrip-
tion and over-the-counter medi-
cations written in lay language.
Herbal product information is
also available through the Na-
tional Center for Complemen-
tary and Integrative Health.
3-FDA
The FDA website contains a
plethora of information that will
help keep you up-to-date. You
can also register to receive up-
dates on new medication ap-
provals and drug recalls. Check
out the newly designed Ap-
proved Drug Products with
Therapeutic Equivalence
Evaluations, also known as the
Orange Book. It has been up-
dated to enable you to search
the resource more efficiently.
The Orange Book shows prod-
ucts that are therapeutically
equivalent for generic drug
substitution.
4-Centers for Disease Con-
trol and Prevention (CDC)
The CDC is the go to resource
for vaccine information. Provide
parents with childhood vaccine
charts. The monthly published
Vitalsigns report provides perti-
nent information on a variety of
health topics including HIV and
injection drug use, prescription
drug abuse, and food safety.
5-Drug Enforcement Ad-
ministration (DEA)
The DEA website provides up-
to-date information on con-
trolled substances that will help
you stay current with federal
laws and regulations. It includes
resources for drug disposal and
the latest reports such as the
2016 National Drug Threat
Assessment. The Question and
Answers tab provides valuable
information on various con-
trolled substance matters in-
cluding prescription drug moni-
toring programs, DEA Form
222, and electronic prescrip-
tions.
Best of luck on your
drug information quest!
Volume 2, Issue 2
22nd JUNE 2017
WEEKLY PHARMA NEWSLETTER
Study co-author Katherine C.
Hughes, of the Harvard T.H.
Chan School of Public Health
in Boston, MA, and colleagues
recently reported their find-
ings in the journal Neurol-
ogy. Low-fat dairy is often
seen as a healthful alternative
to the full-fat kind. But ac-
cording to a new study, con-
suming higher amounts of low
-fat dairy may raise the risk of
Parkinson’s disease. Re-
searchers found that the risk
of Parkinson’s disease was
greater for adults who con-
sumed at least three servings
of low-fat dairy products every
day, compared with those who
consumed just one serving.
5 Free Online Drug Information Resources for a
Pharmacist's Toolbox:
“Low-fat dairy intake may raise
Parkinson’s risk”
PAKISTAN PHARMA CAREER DOOR
NEWSLETTER
5 Free Online Drug
Information Resources
1
L o w - f a t d a i r y i n -
t a k e m a y r a i s e
P a r k i n s o n ’ s r i s k
1
New Drug Approvals in
June 2017.
2
Illegal Drugs in Main-
stream Medicine?
3
Nasal Powder Fixed Severe
Low Blood Sugar
3
List OF FDA Approved
Drugs in 2016
4-7
List OF FDA Approved
Drugs in 2017.
8-10
Info about Pakistan
Pharma Career Door
11
Inside this issue:
SCIENTIFIC HEALTH
BENEFITS OF FASTING:
1. Fasting Promotes detoxifi-
cation
2. Fasting Rests Digestive
System
3. Fasting Resolves Inflam-
matory Response
4. Fasting Reduces Blood
Sugar
5. Fasting Increases Fat
breakdown
6. Fasting Corrects high
blood Pressure
7. Fasting Promotes Weight
loss
8. Fasting Promotes Healthy
diet
9. Fasting Boosts Immunity
10. Fasting May Help to
Overcome Addictions
*************
BY DR.JAVERIYA ANSARI ( PHARMACIST)

2. P A G E 2 P A K I S T A N P H A R M A C A R E E R D O O R
NEW DRUG APPROVALS IN JUNE 2017:

3. To evaluate the newly developed nasal gluca-
gon, researchers gave people with type 1 diabe-
tes a nasal device to use when they had a low
blood sugar episode.
Nasal glucagon is a dry powder that exists in a
small device. It looks something like a na-
sal steroid inhaler, but smaller. To use, a family
member or caregiver takes it out of the con-
tainer, puts it in the nose and pushes the bot-
tom of the canister... It's absorbed through the
nose into the bloodstream.
In the study, 69 people had 157 low blood sugar
TUESDAY, June 13, 2017
For many people with diabetes, low blood sugar
levels are a serious health risk, but researchers
report that a new nasal powder quickly reverses
the effects of this dangerous condition.
The nasal powder contains the hormone Glu-
cagon. This hormone tells the body to release
stored sugar, which will generally reverse
a lowblood sugar episode. Glucagon is currently
only available in an injectable form that has to
be mixed before it is injected.
episodes that were treated with nasal glucagon
In 96 percent of the episodes, blood sugar levels
returned to normal within 30 minutes, the
study found. Side effects were similar to in-
jectable glucagon, including nausea and vomit-
ing. The nasal powder also caused some nasal
irritation and headache. These side effects
tended to last an hour or less, the study found.
Findings from the study were to be pre-
sented soon at the American Diabetes
Association meeting in San Diego.
P A G E 3
ILLEGAL DRUGS IN MAINSTREAM MEDICINE??
Nasal Powder Fixed Severe Low Blood Sugar: ( Article Contributed By Nayab Zehra )
V O L U M E 2 , I S S U E 2
Over the last decade, the science community has started to use Psychedelic drugs, a psychoactive drug whose primary action is to
alter cognition and perception; well known psychedelics include LSD, psilocybin mushrooms, mescaline and DMT, while drugs
such as cannabis and MDMA are also sometimes considered psychedelics. And so these drugs that have been used for recreation
are now finding medicinal purposes .
READERS CONTRIBUTION

4. The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the
United States. Drug information typically includes the drug name, approval status, indication of use, and clinical trial re-
sults.
Cardiology/Vascular Diseases
Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016
Yosprala (aspirin and omeprazole); Aralez Pharmaceuticals; For the prevention of cardiovascular and cerebrovascu-
lar events, Approved September 2016
Dermatology
Ameluz (aminolevulinic acid hydrochloride); Biofrontera Pharma;
For the treatment of actinic keratoses, Approved May 2016
Eucrisa• (crisaborole) ointment; Pfizer; For the treatment of atopic
dermatitis, Approved December 2016
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis, Ap-
proved March 2016
Endocrinology
Adlyxin (lixisenatide); Sanofi Aventis; For the treatment of type II diabe-
tes, Approved July 2016
Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi
Aventis; For the treatment of inadequately controlled type II diabetes, Ap-
proved November 2016
Xultophy 100/3.6 (insulin degludec and liraglutide injection);
Novo Nordisk; For the treatment of inadequately controlled type II diabetes,
Approved November 2016
Family Medicine
Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016
Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi Aventis; For the treatment of inadequately
controlled type II diabetes, Approved November 2016
Xultophy 100/3.6 (insulin degludec and liraglutide injection); Novo Nordisk; For the treatment of inadequately
controlled type II diabetes, Approved November 2016
Gastroenterology
Zinplava (bezlotoxumab); Merck; For the treatment of recurrent Clostridium difficile infection in patients receiving
antibacterial treatment, Approved October 2016
Genetic Disease
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
P A G E 4 P A K I S T A N P H A R M A C A R E E R D O O R
2016 FDA Approved Drugs:

5. Hematology
Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring; For the treatment of hemophillia A,
Approved May 2016
Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein); CSL Behring; For the treatment of
hemophilia B, Approved March 2016
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March
2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma, Approved May 2016
Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April
2016
Hepatology (Liver, Pancreatic, Gall Bladder)
Defitelio (defibrotide sodium); Jazz Pharmaceuticals; For the treatment of hepatic veno-occlusive disease with renal
or pulmonary dysfunction following HSCT, Approved March 2016
Ocaliva (obeticholic acid); Intercept Pharmaceuticals; For the treatment of primary biliary cholangitis, Approved May
2016
Vemlidy (tenofovir alafenamide); Gilead Sciences; For the treatment of chronic hepatitis B , Approved November
2016
Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January
2016
Immunology
Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring; For the treatment of hemophillia A,
Approved May 2016
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April
2016
Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences; For the treatment of hepatitis C, Approved June 2016
Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as
initial therapy, Approved March 2016
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis, Approved March 2016
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016
Infections and Infectious Diseases
Anthim (obiltoxaximab); Elusys Therapeutics; For the treatment of inhalational anthrax , Approved March 2016
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April
2016
Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences; For the treatment of hepatitis C, Approved June 2016
Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as
initial therapy, Approved March 2016
Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nau-
sea and vomiting associated with cancer chemotherapy, Approved July 2016
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016
Vemlidy (tenofovir alafenamide); Gilead Sciences; For the treatment of chronic hepatitis B , Approved November
2016
Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved Jan,2016
Zinplava (bezlotoxumab); Merck; For the treatment of recurrent Clostridium difficile infection in patients receiving
antibacterial treatment, Approved October 2016
P A G E 5 P A K I S T A N P H A R M A C A R E E R D O O R
2016 FDA Approved Drugs:

6. Musculoskeletal
Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of Duchenne muscular dystrophy with mutated DMD
gene amenable to exon 51 skipping, Approved September 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
Zinbryta (daclizumab) ; Biogen; For the treatment of relapsing multiple sclerosis, Approved May 2016
Nephrology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016
Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma, Approved May 2016
Rayaldee (calcifediol) ; Opko Health; For the treatment of secondary hyperparathyroidism in adults with stage 3 or 4
chronic kidney disease, Approved June 2016
Neurology
Briviact (brivaracetam); UCB; For the treatment of partial onset seizures related to epilepsy, Approved February 2016
Carnexiv (carbamazepine); Lundbeck; replacement therapy when oral administration is not feasible, in adults with
seizures, Approved October 2016
Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of Duchenne muscular dystrophy with mutated DMD
gene amenable to exon 51 skipping, Approved September 2016
Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with
Parkinson’s disease, Approved April 2016
Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis, Approved May 2016
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
Troxyca ER (oxycodone + naltrexone); Pfizer; For the management of severe pain, Approved August 2016
Zinbryta (daclizumab) ; Biogen; For the treatment of relapsing multiple sclerosis, Approved May 2016
Obstetrics/Gynecology (Women’s Health)
Intrarosa (prasterone vaginal inser• t); Endoceutics; For the treatment of moderate to severe dyspareunia, a symp-
tom of vulvar and vaginal atrophy, due to menopause, Approved November 2016
Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germ-
line or somatic BRCA mutation, Approved December 2016
Oncology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016
Keytruda (pembrolizumab); Merck; For the treatment of head and neck squamous cell cancer , Approved August 2016
Lartruvo (olaratumab) ; Eli Lilly; For the treatment of soft tissue sarcoma, Approved October 2016
Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma, Approved May 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma, Approved May 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of recurrent or metastatic squamous cell carcinoma of
the head and neck, Approved November 2016
Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germ-
line or somatic BRCA mutation, Approved December 2016
Sustol (granisetron); Heron Therapeutics; For the prevention of chemotherapy-induced nausea and vomiting, Ap-
proved August 2016
Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nau-
sea and vomiting associated with cancer chemotherapy, Approved July 2016
P A G E 6 P A K I S T A N P H A R M A C A R E E R D O O R
2016 FDA Approved Drugs:

7. Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung
cancer, Approved May 2016
Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April
2016
Ophthalmology
Humira (adalimumab); Abbvie; For the treatment of uveitis, Approved July 2016
Xiidra (lifitegrast); Shire; For the treatment of dry eye disease, Approved
July 2016
Pediatrics/Neonatology
Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of
Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51
skipping, Approved September 2016
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the
treatment of hemophillia A, Approved March 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atro-
phy, Approved December 2016
Pharmacology/Toxicology
Sustol (granisetron); Heron Therapeutics; For the prevention of chemo-
therapy-induced nausea and vomiting, Approved August 2016
Psychiatry/Psychology
Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis, Approved May 2016
Pulmonary/Respiratory Diseases
Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca; For the treatment of chronic ob-
structive pulmonary disease, Approved April 2016
Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe asthma, Approved March 2016
Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung
cancer, Approved May 2016
Urology
Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung
cancer, Approved May 2016
Vaccines
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016
P A G E 7 P A K I S T A N P H A R M A C A R E E R D O O R
2016 FDA Approved Drugs:

8. Dermatology
Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017
Dupixent (dupilumab); Regeneron Pharmaceuticals; For the treatment of atopic dermatitis, Approved March 2017
Rhofade (oxymetazoline hydrochloride); Allergan; For the treatment of facial erythema associated with rosacea,
Approved January 2017
Siliq (brodalumab); Valeant Pharmaceuticals; For the treatment of plaque psoriasis , Approved February 2017
Endocrinology
Parsabiv (etelcalcetide); Amgen; For the treatment of secondary hyperparathyroidism in adults with chronic kidney
disease on hemodialysis, Approved February 2017
Qtern (dapagliflozin and saxagliptin) ; AstraZeneca; For the treatment of inadequately controlled type II diabetes ,
Approved February 2017
Family Medicine
Qtern (dapagliflozin and saxagliptin) ; AstraZeneca; For the treatment
of inadequately controlled type II diabetes , Approved February 2017
Trulance (plecanatide); Synergy Pharmaceuticals; For the treatment of
adults with chronic idiopathic constipation, Approved January 2017
Gastroenterology
Symproic (naldemedine); Shionogi; For the treatment of opioid-induced constipation, Approved March 2017
Trulance (plecanatide); Synergy Pharmaceuticals; For the treatment of adults with chronic idiopathic constipation,
Approved January 2017
Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved
February 2017
Genetic Disease
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Ap-
proved April 2017
Hematology
Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Ap-
proved April 2017
Immunology
Ocrevus (ocrelizumab); Genentech; For the treatment of multiple sclerosis, Approved March 2017
Zerviate (cetirizine ophthalmic solution 0.24%); NicOx; For the treatment of ocular itching associated with allergic
conjunctivitis, Approved May 2017
P A G E 8 P A K I S T A N P H A R M A C A R E E R D O O R
“Winning doesn’t always mean being first, winning
means you’re doing better than you’ve done before.”
- Bonnie Blair
2017 FDA Approved Drugs:

9. Musculoskeletal
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Ap-
proved April 2017
Emflaza (deflazacort); Marathon Pharmaceuticals; For the treatment of Duchenne muscular dystrophy, Approved Feb-
ruary 2017
Kevzara (sarilumab); Sanofi ; For the treatment of active rheumatoid arthritis, Approved May 2017
Ocrevus (ocrelizumab); Genentech; For the treatment of multiple sclerosis, Approved March 2017
Tymlos (abaloparatide) ; Radius Health; For the treatment of postmenopausal women with osteoporosis at high risk
for fracture, Approved April 2017
Nephrology
Parsabiv (etelcalcetide); Amgen; For the treatment of secondary hyperparathyroidism in adults with chronic kidney
disease on hemodialysis, Approved February 2017
Neurology
Austedo (deutetrabenazine) ; Teva Pharmaceuticals; For the treatment
of chorea associated with Huntington’s disease, Approved April 2017
Brineura (cerliponase alfa); BioMarin; For the treatment of late infan-
tile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Ingrezza (valbenazine); Neurocrine Biosciences; For the treatment of
tardive dyskinesia, Approved April 2017
Radicava (edaravone); Mitsubishi Tanabe Pharma; For the treatment of
amyotrophic lateral sclerosis , Approved May 2017
Xadago (safinamide); Newron Pharmaceuticals; For the treatment of Parkinson's disease, Approved March 2017
Obstetrics/Gynecology (Women’s Health)
Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017
Tymlos (abaloparatide) ; Radius Health; For the treatment of postmenopausal women with osteoporosis at high risk
for fracture, Approved April 2017
Zejula (niraparib); Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal can-
cer , Approved March 2017
Oncology
Alunbrig (brigatinib); Ariad Pharmaceuticals; For the treatment of advanced ALK-positive metastatic non-small cell
lung cancer, Approved April 2017
Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017
Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma, Approved May
2017
Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017
Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Ap-
proved April 2017
Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved
February 2017
Zejula (niraparib); Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal can-
cer , Approved March 2017
P A G E 9 P A K I S T A N P H A R M A C A R E E R D O O R
“Hardships often prepare ordinary people
for an extraordinary destiny”
-C.S.LEWIS
2017 FDA Approved Drugs:

10. Ophthalmology
Zerviate (cetirizine ophthalmic solution 0.24%); NicOx; For the treatment of ocular itching associated with allergic
conjunctivitis, Approved May 2017
Pediatrics/Neonatology
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Ap-
proved April 2017
Emflaza (deflazacort); Marathon Pharmaceuticals; For the treatment of Duchenne muscular dystrophy, Approved Feb-
ruary 2017
Rheumatology
Kevzara (sarilumab); Sanofi ; For the treatment of active rheumatoid arthritis, Approved May 2017
Urology
Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma, Approved May
2017
P A G E 1 0 P A K I S T A N P H A R M A C A R E E R D O O R
2017 FDA Approved Drugs:
It is found that “Guanabana”or Tree sour soup,
a magical fruit with ant carcinogenic properties .”

11. Pakistan Pharma Career Door is a Facebook Social Group
created by Javeriya Ansari (Pharmacsit) on 1st November,
2014 with an aim to provide;
* Latest information about the ongoing Pharma Research.
*Information about new discoveries and inventions in the
field of Science.
*Links to Download Pharma related Books and Notes .
* Link to apply for the Job opportunities in Pharmaceuti-
cal Industries .
*Any query regarding the pharma jobs / pharma subject
will be answered on group and email.
For your contribution and suggestions kindly email on:
Javeriya.pharmacist@gmail.com
USEFUL INFORMATION:
LINKTO BLOG:
http://pakpharmacareerdoor.blogspot.com/
WEBLINK:
https://www.facebook.com/groups/
PakPharmacareerdoor/
PAKISTAN PHARMA
CAREER DOOR